We are live on ! Find out more
CRMD icon

CorMedix

198 hedge funds and large institutions have $488M invested in CorMedix in 2025 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 79 increasing their positions, 56 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more call options, than puts

Call options by funds: $28.3M | Put options by funds: $18M

41% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 56

34% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 29

4% more funds holding

Funds holding: 190198 (+8)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

3% less capital invested

Capital invested by funds: $502M → $488M (-$13.8M)

2.01% less ownership

Funds ownership: 55.24%53.24% (-2%)

Holders
198
Holders Change
+8
Holders Change %
+4.21%
% of All Funds
2.4%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
39
Increased
79
Reduced
56
Closed
29
Calls
$28.3M
Puts
$18M
Net Calls
+$10.3M
Net Calls Change
+$9.39M

CRMD Hedge Fund Activity: Q4 2025 in Review

198 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q4 2025, worth a combined $488M — down 2.7% from $502M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new CRMD positions and 29 closed out — a net gain of 10 holders — while 79 added to existing stakes and 56 trimmed.

The largest buyer was Deep Track Capital, adding an estimated $52.8M. The largest seller was Deerfield Management, cutting an estimated $24.5M.

  • 198 institutional investors held CorMedix (CRMD) as of Q4 2025, up from 190 in Q3 2025.
  • Funds reported $488M of CorMedix stock for Q4 2025, down 2.7% quarter-over-quarter.
  • 39 funds opened new CorMedix positions in Q4 2025 and 29 closed out, a net change of +10 holders.
  • The largest CorMedix buyer in Q4 2025 was Deep Track Capital, an estimated $52.8M added.
  • The largest CorMedix seller in Q4 2025 was Deerfield Management, an estimated $24.5M sold.

Based on aggregated 13F filings for Q4 2025.